www.allsides.com
Trump Says World Is Free-Riding on U.S. Health Spending. He Has a Point.
Pharmaceutical companies often invest billions to develop new drugs, with the U.S. market as a crucial target. The benefits extend globally.
Consider the $11 billion acquisition of Pharmasset by Gilead Sciences more than a decade ago, which led to the development of Sovaldi, a groundbreaking hepatitis C treatment. When Sovaldi was launched in the U.S. at $84,000 for a 12-week regimen, it sparked widespread criticism for its high cost. Policymakers and patient...
New Posts (Home)
ChatBox
Popular Posts 
Game Zone
Top PodCasts
